TCTR20220502003招募中3 期
The effectiveness and safety of quality and quantity mononuclear cells in treating chronic limb ischemia patient
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •Patients with CLI presented with rest pain , non-healing ischemic ulcer and toe gangrene for 3 months
排除标准
- •Gangrene extended proximally to forefoot area
- •Recent myocardial infarction
- •Severe valvular heart disease
- •After organ transplantation
- •Cardiomyopthy( EF< 25%)
- •Liver failure
- •Coagulopathy
研究者
相似试验
招募中
不适用
To evaluate the efficacy, safety and QOL(quality of life) of blonanserin monotherapy in schizophrenia patientsMental and behavioral disordersKCT0001105Koera University Guro Hospital100
进行中（未招募）
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2021-003759-40-ESovartis Pharma AG1,760
进行中（未招募）
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersHypercholesterolemiaEUCTR2021-003759-40-DEovartis Pharma AG1,760
进行中（未招募）
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2021-003759-40-LVovartis Pharma AG1,760
进行中（未招募）
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2021-003759-40-EEovartis Pharma AG1,760